Kircik Leon H
Icahn School of Medicine at Mount Sinai, New York, New York; Indiana University Medical Center, Indianapolis; Physicians Skin Care, Louisville, Kentucky; DermResearch, PLLC, Louisville; and Skin Sciences, PLLC, Louisville, USA.
Cutis. 2019 Jul;104(1):48-52.
Drug development continues to focus on the challenge of treating acne effectively and safely. Inflammation is a backdrop to the commonly cited elements of the pathophysiology of acne: Propionibacterium acnes proliferation, increased sebum production with an increase in circulating androgens, and faulty keratinization. As such, there is increased emphasis on targeting inflammation and its effects. Vehicle innovations are optimizing existing active drugs and creating opportunities to deliver new compounds to the skin. Recently approved sarecycline is the first new chemical entity approved for acne in several years. It might be followed in coming years by other new actives, including clascoterone and cannabidiol (CBD).
药物研发仍聚焦于有效且安全地治疗痤疮这一挑战。炎症是痤疮病理生理学中常见因素的背景：痤疮丙酸杆菌增殖、随着循环雄激素增加皮脂分泌增多以及角质化异常。因此，越来越强调针对炎症及其影响。载体创新正在优化现有的活性药物，并为向皮肤递送新化合物创造机会。最近获批的丝柔四环素是数年来首个获批用于治疗痤疮的新化学实体。未来几年可能会有其他新活性药物相继出现，包括氯睾酮和大麻二酚（CBD）。
